Literature DB >> 11051055

Appropriate timing of glimepiride administration in patients with type 2 diabetes millitus: a study in Mediterranean countries.

R Gomis1, S A Raptis, R Ravella.   

Abstract

Sulfonylureas are used to treat patients with type 2 diabetes mellitus when diet and exercise fail. Glimepiride, a new sulfonylurea, can be administered in one daily dose, thanks to its pharmacokinetic properties. We attempted to establish the optimal time of day for the administration of Glimepiride in a group of patients from the Mediterranean area by clinical trial. No relationship was found between the time of administration and fasting blood glucose values, or HbA1c, or the frequency or severity of hypoglycemic episodes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11051055     DOI: 10.1385/ENDO:13:1:117

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  12 in total

1.  A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999.

Authors: 
Journal:  Diabet Med       Date:  1999-09       Impact factor: 4.359

2.  Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.

Authors:  P S van der Wal; K E Draeger; A M van Iperen; C Martini; M Aarsen; R J Heine
Journal:  Diabet Med       Date:  1997-07       Impact factor: 4.359

Review 3.  An overview of the safety and tolerance of glimepiride.

Authors:  J Schneider
Journal:  Horm Metab Res       Date:  1996-09       Impact factor: 2.936

Review 4.  Glimepiride. A review of its use in the management of type 2 diabetes mellitus.

Authors:  H D Langtry; J A Balfour
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

5.  Sulphonylureas and hypoglycaemia.

Authors:  R E Ferner; H A Neil
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-02

Review 6.  Oral antidiabetic agents. A guide to selection.

Authors:  A J Scheen; P J Lefèbvre
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

7.  Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide.

Authors:  K E Draeger; K Wernicke-Panten; H J Lomp; E Schüler; R Rosskamp
Journal:  Horm Metab Res       Date:  1996-09       Impact factor: 2.936

8.  Glibenclamide-associated hypoglycaemia: a report on 57 cases.

Authors:  K Asplund; B E Wiholm; F Lithner
Journal:  Diabetologia       Date:  1983-06       Impact factor: 10.122

9.  United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.

Authors:  R Turner; C Cull; R Holman
Journal:  Ann Intern Med       Date:  1996-01-01       Impact factor: 25.391

10.  U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.

Authors: 
Journal:  Diabetes       Date:  1995-11       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.